HALOZYME THERAPEUTICS, INC.HALOEarnings & Financial Report
Nasdaq
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
NextMar 13, 2026
HALO Q3 2025 Key Financial Metrics
Revenue
$354.3M
Gross Profit
$299.0M
Operating Profit
$217.9M
Net Profit
$175.2M
Gross Margin
84.4%
Operating Margin
61.5%
Net Margin
49.5%
YoY Growth
22.1%
EPS
$1.43
Financial Flow
HALOZYME THERAPEUTICS, INC. Q3 2025 Financial Summary
HALOZYME THERAPEUTICS, INC. reported revenue of $354.3M for Q3 2025, with a net profit of $175.2M (49.5% margin). Cost of goods sold was $55.2M, operating expenses totaled $81.1M.
Key Financial Metrics
| Total Revenue | $354.3M |
|---|---|
| Net Profit | $175.2M |
| Gross Margin | 84.4% |
| Operating Margin | 61.5% |
| Report Period | Q3 2025 |
HALOZYME THERAPEUTICS, INC. Annual Revenue by Year
HALOZYME THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.0B).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.0B |
| 2023 | $829.3M |
| 2022 | $660.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $230.0M | $195.9M | $231.4M | $290.1M | $298.0M | $264.9M | $325.7M | $354.3M |
| YoY Growth | 26.7% | 20.8% | 4.7% | 34.3% | 29.5% | 35.2% | 40.8% | 22.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.73B | $1.84B | $1.97B | $2.12B | $2.06B | $2.20B | $2.05B | $2.22B |
| Liabilities | $1.65B | $1.66B | $1.68B | $1.67B | $1.70B | $1.71B | $1.72B | $1.72B |
| Equity | $83.8M | $177.8M | $289.4M | $452.7M | $363.8M | $482.3M | $332.7M | $503.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $102.4M | $129.4M | $55.8M | $115.4M | $178.5M | $154.2M | $99.7M | $178.6M |